Sunday, 06 December 2015 16:19

Anticoagulation news items. Weeks commencing 9th, 16th and 23rd November 2015

edoxaban (Lixiana) for the prevention of stroke and systemic embolism

Scottish Medicines Consortium

The SMC has accepted for use within NHS Scotland, edoxaban (Lixiana®) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as CHF, hypertension, age ≥75 years, DM, prior stroke or TIA.

 

edoxaban (Lixiana) for the treatment of DVT and PE

Scottish Medicines Consortium

The Scottish Medicines Consortium has accepted for use within NHS Scotland, edoxaban (Lixiana®) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

 

FDA Drug Safety Communication: Review finds long-term treatment with clopidogrel does not change risk of death

US Food and Drug Administration

This review stated that long-term use (12 months or longer) of clopidogrel does not increase or decrease overall risk of death in patients with, or at risk for, heart disease. The evaluation also does not suggest that clopidogrel increases the risk of cancer or death from cancer.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services